ABSTRACT
It has become increasingly clear that the immune system can play a critical role in the pathophysiology of certain psychiatric disorders. For immune-mediated psychiatric illness, various forms of immunosuppressive therapy have been utilized. In this context, hematopoietic stem cell transplantation (HSCT) remains a theoretical consideration for treatment of patients who present with an immune-mediated psychiatric disorder. For such severe disorders, the best HSCT regimen and patient selection is yet to be defined. At the present time, HSCT should only be undertaken by an experienced team under an institutional review board-approved and monitored protocol with an outside data safety monitoring board.
